Wenig J A
89th Medical Group, Malcolm Grow Medical Center, Andrews Air Force Base, Maryland, USA.
Clin Podiatr Med Surg. 1995 Apr;12(2):263-74.
The systemic treatment of fungal infections has changed considerably over the past 10 to 20 years. Griseofulvin, the only drug approved by the Food and Drug Administration for the systemic treatment of onychomycosis, has a cure rate that seldom exceeds 40%. Many new drugs are targeting the three main kinds of drug therapy for fungal nails: reduction of treatment times, improvement of cure rates with a minimum of side effects, and the achievement of long-term remissions in recalcitrant infections. As the public becomes aware of newer therapies, we will see more patients with nail infections. Although these new agents for superficial fungal infections are not yet approved in the United States, they have been used extensively in Europe.
在过去10到20年里，真菌感染的全身治疗发生了很大变化。灰黄霉素是美国食品药品监督管理局批准的唯一用于甲癣全身治疗的药物，其治愈率很少超过40%。许多新药针对治疗灰指甲的三种主要药物疗法：缩短治疗时间、以最少的副作用提高治愈率，以及在顽固性感染中实现长期缓解。随着公众对更新疗法的了解，我们将会看到更多患有指甲感染的患者。尽管这些用于浅表真菌感染的新药在美国尚未获批，但它们在欧洲已被广泛使用。
